1-6 of 6
Sher Karki, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts

Nandini Rudra-Ganguly, PhD, Christine Lowe, Cyrus Virata, Monica Leavitt, Liqing Jin, MD, Brian Mendelsohn, PhD, Josh Snyder, Hector Aviña, Chunying Zhang, Deanna L Russell, Michael Mattie, PhD, Peng Yang, PhD, Baljinder Randhawa, Gao Liu, Faisal Malik, Misty Vest, Joseph D Abad, Christopher C Kemball, PhD, René Hubert, PhD, Sher Karki, PhD, Banmeet Anand, PhD, Zili An, MD, Jeanette Grant, PhD, John E. Dick, PhD, Fernando Doñate, PhD, Kendall Morrison, PhD, Pia Challita-Eid, PhD, Ingrid B Joseph, DVM, PhD, Daniel S. Pereira, PhD, David R. Stover, PhD
Journal: Blood
Blood (2015) 126 (23): 3806.
https://doi.org/10.1182/blood.V126.23.3806.3806
Published: 2015
Journal Articles

An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

Eugene A. Zhukovsky, PhD, Holly Horton, Ph.D, Matthias Peipp, PhD, Erik Pong, BS, Matthew Bernett, PhD, Sher Karki, PhD, John Richards, PhD, Seung Chu, PhD, Roland Repp, MD, John Desjarlais, PhD
Journal: Blood
Blood (2008) 112 (11): 881.
https://doi.org/10.1182/blood.V112.11.881.881
Published: 2008
Journal Articles

XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies

Chris E Lawrence, PhD, Jonathan Zalevsky, PhD, Holly Horton, PhD, Irene Leung, PhD, Seung Chu, PhD, Sher Karki, PhD, Eugene Zhukovsky, PhD, John R Desjarlais, PhD, David F Carmichael, PhD
Journal: Blood
Blood (2008) 112 (11): 2621.
https://doi.org/10.1182/blood.V112.11.2621.2621
Published: 2008
Journal Articles

XmAb™ Fc Engineered Anti-CD19 Monoclonal Antibody with Enhanced In Vitro Efficacy Against Lymphoma and Leukemia.

Eugene Zhukovsky, PhD, Seung Chu, PhD, Matthew Bernett, PhD, Sher Karki, PhD, John Richards, PhD, Erik Pong, BS, Matthias Peipp, PhD, Roland Repp, MD, John Desjarlais, PhD
Journal: Blood
Blood (2007) 110 (11): 2335.
https://doi.org/10.1182/blood.V110.11.2335.2335
Published: 2007
Journal Articles

XmAb™2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies.

Chris E. Lawrence, PhD, Phil W. Hammond, PhD, Jonathan Zalevsky, PhD, Holly Horton, PhD, Seung Chu, PhD, Sher Karki, PhD, John R. Desjarlais, PhD, David F. Carmichael, PhD
Journal: Blood
Blood (2007) 110 (11): 2340.
https://doi.org/10.1182/blood.V110.11.2340.2340
Published: 2007
Journal Articles

Improving the Efficacy of Rituxan by Rational Protein Engineering.

Greg Lazar, PhD, Wei Dang, PhD, Omid Vafa, PhD, Sher Karki, PhD, Jost Vielmetter, PhD, Stephen Doberstein, PhD, David Carmichael, PhD, Robert Hayes, PhD
Journal: Blood
Blood (2004) 104 (11): 1405.
https://doi.org/10.1182/blood.V104.11.1405.1405
Published: 2004